OCWP
VRDN icon

Owl Creek Wealth Partners’s Viridian Therapeutics VRDN Stock Holding History

Owl Creek Wealth Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$827 Hold
45
– – ﹤0.01% 1229
2026
Q1 		$881 Buy
+45
New +$1.34K ﹤0.01% 1175

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Owl Creek Wealth Partners's VRDN Position: Q2 2026 in Review

Owl Creek Wealth Partners held its Viridian Therapeutics (VRDN) position steady in Q2 2026 at 45 shares worth $827. The position accounts for ﹤0.01% of the portfolio, ranked #1229.

Owl Creek Wealth Partners first reported a position in VRDN in Q1 2026 and has held it in 2 quarters since. The position peaked at $881 in Q1 2026. 193 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Owl Creek Wealth Partners held 45 shares of Viridian Therapeutics worth $827 as of Q2 2026.
  • Owl Creek Wealth Partners left its Viridian Therapeutics share count unchanged in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #1229 holding.
  • Owl Creek Wealth Partners first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Owl Creek Wealth Partners's Viridian Therapeutics position peaked at $881 in Q1 2026.
  • 193 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.